Rebound Making Wockhardt An Acquisition Target?
This article was originally published in PharmAsia News
Executive Summary
Despite its problems with the U.S. FDA, Wockhardt appears to have rebounded to the extent that it may have made itself a possible acquisition target, including by its fellow Indian drug maker, Lupin.